Chief, Myeloma Service
Myeloma Specialist and Cellular Therapist
Memorial Sloan Kettering Cancer Center

Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He joined the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences in Little Rock in 2010 as the director of developmental therapeutics. He was recruited to the Levine Cancer Institute/Atrium Health in 2013 as the inaugural division chief of plasma cell disorders and director of clinical research for hematologic malignancies where he built an internationally renowned myeloma program. He joined Memorial Sloan Kettering Cancer Center in 2021 as the chief of myeloma service and holds a faculty position as professor of clinical medicine at Weill Cornell Medical College, Cornell University. Dr. Usmani is board-certified in internal medicine, medical oncology, and hematology. He is a fellow of the American College of Physicians, fellow of the Royal College of Physicians (UK), and fellow of the American Society of Clinical Oncology (ASCO). He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group (Scientific Advisory Board member), the ALLIANCE Myeloma National Clinical Trials Network Committee (chair), the American Society of Hematology (ASH), ASCO, International Myeloma Society (board member), the American Society for Transplantation and Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has served as the vice chair of the SWOG Myeloma Committee and as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, as well as on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders. He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, the Controversies in Multiple Myeloma Award for Excellence in Myeloma Research, the Leukemia & Lymphoma Society (LLS) Scholar in Clinical Research, the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research, and the LLS Career Development Program Achievement Award. He has led the clinical development of several novel therapies, including anti-CD38 monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor-T cell therapies, resulting in regulatory approvals in multiple myeloma. Dr. Usmani has authored/co-authored more than 300 peer-reviewed research manuscripts (New England Journal of Medicine, The Lancet, Nature Medicine, Journal of Clinical Oncology, Cancer Cell, Blood, Leukemia, etc). Active in clinical and translational research, Dr. Usmani has research interests focused on plasma cell disorders—in particular, high-risk multiple myeloma.

Assistant Professor, Division of Hematology and Oncology​
University of Washington​
Assistant Professor, Clinical Research Division​
Fred Hutchinson Cancer Center​
Seattle, WA​

Rahul Banerjee, MD, is a physician-researcher who specializes in multiple myeloma, a blood cancer caused by plasma cells that can cause bone and kidney damage. Dr. Banerjee also treats patients with amyloid light-chain amyloidosis, a related but rarer condition that is treated similarly through close collaboration between cancer doctors, kidney doctors, and heart doctors. He has a particular research interest in cellular immunotherapies such as chimeric antigen receptor-T cell therapies, where the patient’s immune cells are genetically modified to recognize and eliminate tumor cells. He is a member of the International Myeloma Working Group and has published over 70 peer-reviewed publications with an emphasis on improving the experiences of patients as they undergo treatment for multiple myeloma.

Assistant Member
Blood and Marrow Transplant and Cellular Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Assistant Professor
Department of Oncologic Science
Morsani College of Medicine
University of South Florida
Tampa, FL

Dr. Hansen is an Assistant Member/Professor in the Department of Blood and Marrow Transplant and Cellular Immunotherapy, and a practicing hematologist integrated in the Immune Cell Therapy (ICE-T) Program at Moffitt Cancer Center and the University of South Florida/Morsani College of Medicine. Her clinical and research interests include utilizing autologous transplantation and cellular immunotherapies to treat and improve outcomes for patients with multiple myeloma. Dr. Hansen’s research interest focuses on characterizing both clinical and patient-reported outcomes among individuals with multiple myeloma receiving immunotherapies, as well as identifying the impact of inflammation and immunity on toxicity and efficacy in this patient population.

Associate Professor, Department of Hematology and Medical Oncology
Multiple Myeloma Working Group Lead
Winship Cancer Institute, Emory University
Atlanta, GA

Nisha S. Joseph, MD is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Joseph was named the first H. Jean Khoury Fellow in Leukemia and Bone Marrow Transplant. Board certified in hematology and medical oncology, she specializes in plasma cell disorders and bone marrow transplant.

She received her medical degree from The Ohio State University School of Medicine in Columbus. She completed both her residency in internal medicine and her fellowship in hematology and medical oncology at Emory University, where she served as chief fellow in her final year. She currently leads the myeloma clinical trial working group and serves as the hematology course director in the Emory University School of Medicine.

Assistant Attending, Myeloma Service
Department of Medicine, Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Tan, is a board-certified hematologist and oncologist specializing in the treatment of multiple myeloma and other related plasma cell disorders. She is part of a multidisciplinary team caring for people with these conditions. She joined Memorial Sloan Kettering in 2020 and has experience in treating blood cancers, with a focus on multiple myeloma, lymphoma, and bone marrow transplant and cellular therapy.

During her years in fellowship training, she became interested in hematologic malignancies, specifically multiple myeloma. She believes that a better understanding of the underlying biology behind multiple myeloma and its interaction with and evasion of the immune system will lead to improved therapies and outcomes. Her specific research interests include the development of innovative therapeutic approaches for the management of multiple myeloma and the exploration of biomarkers to predict and track responses to these therapies. She also is working to develop methods and interventions to address short-term and long-term toxicities from currently available therapies. Dr. Tan is involved in a number of clinical trials evaluating novel therapeutic approaches for the treatment of multiple myeloma, including chimeric antigen receptor-T cell therapies.